Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
Department of Molecular Medicine and Biopharmaceutical Science, Seoul National University, Seoul, Republic of Korea.
Eur Heart J. 2024 Sep 29;45(36):3721-3731. doi: 10.1093/eurheartj/ehae462.
Patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) are at increased risk of not only bleeding, but also ischaemic events. This study aimed to determine the long-term relative risk of ischaemic and bleeding events in HBR patients.
This study was a nationwide cohort study, based on the Korean National Health Insurance Review and Assessment Service database. Patients diagnosed with stable angina or acute coronary syndrome and those who underwent PCI in Korea between 2009 and 2018 were included in the analysis. According to the Academic Research Consortium HBR criteria, the total population was divided into HBR and non-HBR groups. The co-primary outcomes were major bleeding events and ischaemic (composite of cardiac death, myocardial infarction, and ischaemic stroke) events.
Among a total of 325 417 patients who underwent PCI, 66 426 patients (20.4%) had HBR. During the follow-up period, HBR patients had a higher risk for major bleeding events (23.9% vs. 8.9%, P < .001) and ischaemic events (33.8% vs. 14.4%, P < .001). However, the impact of HBR was significant for major bleeding events [hazard ratio (HR) 3.12, 95% confidence interval (CI) 3.04-3.21, P < .001] and for ischaemic events (HR 2.50, 95% CI 2.45-2.56, P < .001). The HBR group was also associated with a greater risk of all-cause mortality (HR 3.73, 95% CI 3.66-3.79, P < .001). The average annual rate of major bleeding events within the first year after PCI was 5.5% for a single major criterion, and 2.9% for a single minor criterion.
Among patients undergoing PCI, those with HBR were at increased long-term risk for both bleeding and ischaemic events, with a greater risk of mortality compared to non-HBR patients.
接受经皮冠状动脉介入治疗(PCI)的高出血风险(HBR)患者不仅出血风险增加,而且发生缺血事件的风险也增加。本研究旨在确定 HBR 患者发生缺血和出血事件的长期相对风险。
这是一项全国性队列研究,基于韩国国家健康保险审查和评估服务数据库。纳入 2009 年至 2018 年期间在韩国诊断为稳定型心绞痛或急性冠状动脉综合征并接受 PCI 的患者。根据学术研究联合会 HBR 标准,将总人群分为 HBR 和非 HBR 组。主要复合终点为大出血事件和缺血事件(包括心源性死亡、心肌梗死和缺血性卒中)。
在总共 325417 例接受 PCI 的患者中,66426 例(20.4%)存在 HBR。在随访期间,HBR 患者发生大出血事件的风险更高(23.9% vs. 8.9%,P <.001)和缺血事件(33.8% vs. 14.4%,P <.001)。然而,HBR 对大出血事件(风险比[HR] 3.12,95%置信区间[CI] 3.04-3.21,P <.001)和缺血事件(HR 2.50,95% CI 2.45-2.56,P <.001)均有显著影响。HBR 组也与全因死亡率增加相关(HR 3.73,95% CI 3.66-3.79,P <.001)。PCI 后第一年,主要标准单一事件大出血的平均年发生率为 5.5%,次要标准单一事件大出血的发生率为 2.9%。
在接受 PCI 的患者中,HBR 患者出血和缺血事件的长期风险均增加,与非 HBR 患者相比,死亡率更高。